Dolor Therapeutics, Inc.

Dolor Therapeutics is a preclinical-stage pharmaceutical company dedicated to developing novel treatments for urologic conditions with high unmet medical needs. Spun out of Northwestern University's Feinberg School of Medicine, the company focuses on the intersection of immune and neuronal dysfunction to address chronic pain and inflammatory disorders of the urinary tract. The company's research is rooted in the work of Dr. Praveen Thumbikat, focusing on the pathogenic mechanisms of chronic pelvic pain syndrome (CPPS), bacterial prostatitis, and benign prostatic hyperplasia (BPH). By targeting neuroinflammation and fibrosis mediated by mast cells and T cells, Dolor Therapeutics aims to provide disease-modifying therapies rather than just symptomatic relief.